Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity
Science Advances · 11.10.2024 · 10 (41)
DOI: 10.1126/sciadv.adn9961 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 11.10.2024. Verfasst von Ting Fan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Antigens, Neoplasm. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
mRNA neoantigen cancer vaccine inducing neoantigen-specific T cell responses holds great promise for cancer immunotherapy; however, its clinical translation remains challenging because of suboptimal neoantigen prediction accuracy and low delivery efficiency, which compromise the in vivo therapeutic efficacy. We present a lipopolyplex (LPP)–formulated mRNA cancer vaccine encoding tandem neoantigens as a cancer therapeutic regimen. The LPP-formulated mRNA vaccines elicited robust neoantigen-specific CD8 + T cell responses in three syngeneic murine tumor models (CT26, MC38, and B16F10) to suppress tumor growth. Prophylactic cancer vaccine treatment completely prevented tumor development, and long-lasting memory T cells protected mice from tumor cell rechallenge. Combining the vaccine with immune checkpoint inhibitor further boosted the antitumor activity. Of note, LPP-based personalized cancer vaccine was administered in two cancer patients and induced meaningful neoantigen-specific T cell and clinical responses. In conclusion, we demonstrated that the LPP-based mRNA vaccine can elicit strong antitumor immune responses, and the results support further clinical evaluation of the therapeutic mRNA cancer vaccine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China.
- StemiRNA Therapeutics Inc., Shanghai, China.
- Biomedical Polymers Laboratory, College of Chemistry Chemical Engineering and Materials Science and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou 215123, China.
- International College of Pharmaceutical Innovation, Soochow University, Suzhou 215123, China.
- College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
- Department of Pharmacology & Therapeutics and Experimental Therapeutics (ET) Graduate Program, University at Buffalo and Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
ORCID-Profile: Ting Fan, Congcong Xu, Jichuan Wu, Wanlu Cao, Haifa Shen, Lei Huang, Qianyun Li, Bo Yu, Chunxiu Chen, Fengjia Chen, Anmbreen Jamroze, Dean G Tang, Hangwen Li, Chunyan Dong
Förderung
- NCI NIH HHS
Zitieren
APA
Fan, T., Xu, C., Wu, J., Cai, Y., Cao, W., Shen, H., Zhang, M., Zhu, H., Yang, J., Zhu, Z., Ma, X., Ren, J., Huang, L., Li, Q., Tang, Y., Yu, B., Chen, C., Xu, M., Wang, Q., …, & Dong, C. (2024). Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Science Advances, 10(41). https://doi.org/10.1126/sciadv.adn9961
Vancouver
Fan T, Xu C, Wu J, Cai Y, Cao W, Shen H, et al. Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity. Science Advances. 2024;10(41). doi:10.1126/sciadv.adn9961
BibTeX
@article{Fan2024,
author = {Fan, Ting and Xu, Congcong and Wu, Jichuan and Cai, Yihua and Cao, Wanlu and Shen, Haifa and Zhang, Mingna and Zhu, Hanfei and Yang, Jingxian and Zhu, Zhounan and Ma, Xiaopin and Ren, Jiale and Huang, Lei and Li, Qianyun and Tang, Yuying and Yu, Bo and Chen, Chunxiu and Xu, Mingcheng and Wang, Qiuhe and Xu, Zhuya and Chen, Fengjia and Liang, Shujing and Zhong, Zhixian and Jamroze, Anmbreen and Tang, Dean G and Li, Hangwen and Dong, Chunyan},
title = {Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {41},
doi = {10.1126/sciadv.adn9961}
}
EUVIMED